Prognostic impact of clonal hematopoiesis mutations at complete molecular remission in acute myeloid leukemia with NPM1 mutation.
Humans
Nucleophosmin
Leukemia, Myeloid, Acute
/ genetics
Male
Middle Aged
Female
Mutation
Clonal Hematopoiesis
/ genetics
Prognosis
Adult
Nuclear Proteins
/ genetics
Remission Induction
Aged
Young Adult
DNA Methyltransferase 3A
Adolescent
Hematopoietic Stem Cell Transplantation
Retrospective Studies
Dioxygenases
DNA-Binding Proteins
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
18 Oct 2024
18 Oct 2024
Historique:
received:
02
06
2024
accepted:
14
10
2024
medline:
18
10
2024
pubmed:
18
10
2024
entrez:
18
10
2024
Statut:
epublish
Résumé
The prognostic impact of clonal hematopoiesis (CH) in complete molecular remission (CMR) in acute myeloid leukemia (AML) remains controversial. Here, we explored the prognosis of CH-related gene mutations (CH-mutation) at CMR in patients with AML with NPM1 mutation (NPM1c AML). Ninety-one patients with de novo NPM1c AML were included between June 2018 and June 2023, including 32 patients with CH-related mutation at CMR and 59 patients without. A cutoff of ≥ 2.0% for variant allele frequency (VAF) of residual mutations was used to define CH-mutation at CMR. Thirty-two patients with CH-mutation at CMR had a greater median age and higher white blood cell (WBC) counts than those without (median age, 50.5 and 45 years, respectively; p = 0.028 and WBC count: 34.5 and 10 × 10
Identifiants
pubmed: 39422784
doi: 10.1007/s00432-024-05999-6
pii: 10.1007/s00432-024-05999-6
doi:
Substances chimiques
Nucleophosmin
117896-08-9
NPM1 protein, human
0
Nuclear Proteins
0
DNMT3A protein, human
0
DNA Methyltransferase 3A
EC 2.1.1.37
TET2 protein, human
EC 1.13.11.-
Dioxygenases
EC 1.13.11.-
DNA-Binding Proteins
0
Types de publication
Journal Article
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
465Subventions
Organisme : Medical Science and Technology Development Plan Project of Yancheng
ID : YK2015009
Organisme : Gusu Talent Program
ID : GSWS2022012
Organisme : National Natural Science Foundation of China
ID : 82100170
Organisme : National Natural Science Foundation of China
ID : 82170158
Organisme : Natural Science Foundation of Jiangsu Province
ID : BK20210087
Organisme : National Key R&D Program of China
ID : 2019YFA0111004
Organisme : Translational Research Grant of NCRCH
ID : 2021WSB01
Organisme : Open Project of Jiangsu Biobank of Clinical Resources
ID : SBK202003001
Informations de copyright
© 2024. The Author(s).
Références
Cappelli LV, Meggendorfer M, Baer C et al (2022) Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration. Leukemia 36:394–402. https://doi.org/10.1038/s41375-021-01368-1
doi: 10.1038/s41375-021-01368-1
pubmed: 34376804
Cocciardi S, Dolnik A, Kapp-Schwoerer S et al (2019) Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. Nat Commun. https://doi.org/10.1038/s41467-019-09745-2 . 10:2031
doi: 10.1038/s41467-019-09745-2
pubmed: 31048683
pmcid: 6497712
Grimm J, Bill M, Jentzsch M et al (2019) Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation. Bone Marrow Transpl 54:1189–1197. https://doi.org/10.1038/s41409-018-0413-0
doi: 10.1038/s41409-018-0413-0
Hasserjian RP, Steensma DP, Graubert TA, Ebert BL (2020) Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia. Blood 135:1729–1738. https://doi.org/10.1182/blood.2019004770
doi: 10.1182/blood.2019004770
pubmed: 32232484
pmcid: 7225688
Höllein A, Meggendorfer M, Dicker F et al (2018) NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse. Blood Adv 2:3118–3125. https://doi.org/10.1182/bloodadvances.2018023432
doi: 10.1182/bloodadvances.2018023432
pubmed: 30455361
pmcid: 6258925
Jongen-Lavrencic M, Grob T, Hanekamp D et al (2018) Molecular minimal residual disease in Acute myeloid leukemia. N Engl J Med 378(13):1189–1199. https://doi.org/10.1056/NEJMoal1716863
doi: 10.1056/NEJMoal1716863
pubmed: 29601269
Morita K, Kantarjian HM, Wang F et al (2018) Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia. J Clin Oncol 36:1788–1797. https://doi.org/10.1200/JCO.2017.77.6757
doi: 10.1200/JCO.2017.77.6757
pubmed: 29702001
pmcid: 6008108
Rothenberg-Thurley M, Amler S, Goerlich D et al (2018) Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. Leukemia 32:1598–1608. https://doi.org/10.1038/s41375-018-0034-z
doi: 10.1038/s41375-018-0034-z
pubmed: 29472724
pmcid: 6035153
Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, Ebert BL (2015) Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126:9–16. https://doi.org/10.1182/blood-2015-03-631747
doi: 10.1182/blood-2015-03-631747
pubmed: 25931582
pmcid: 4624443
Tanaka T, Morita K, Loghavi S et al (2021) Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. Blood 138:1733–1739. https://doi.org/10.1182/blood.2020010483
doi: 10.1182/blood.2020010483
pubmed: 34115096
pmcid: 8569418